Clinically relevant improvements in asthma-related quality of life in patients receiving omalizumab as add-on therapy

被引：1
|
作者：
Busse, W
Fox, H
Surrey, K
Maykut, R
Reisner, C
机构：
[1] Univ Wisconsin, Dept Med, Madison, WI 53706 USA
[2] Novartis Horsham Res Ctr, Horsham, W Sussex, England
[3] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2006年 / 117卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2005.12.033
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
30
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [21] Clinically meaningful improvements in asthma control questionnaire (ACQ) scores occur early, while asthma-related quality of life (AQLQ) scores continue to improve over 52 weeks, among patients with eosinophilic asthma receiving IV reslizumab
    Hickey, Lisa
    Carr, Warner
    Garin, Margaret
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB96 - AB96
  • [22] Quality of life and asthma control with omalizumab therapy
    Vieira, T.
    Ferraz de Oliveira, J.
    Castel-Branco, M.
    ALLERGY, 2011, 66 : 365 - 365
  • [23] Efficacy of omalizumab in allergic asthma patients at high-risk for asthma-related death
    Bousquet, J
    Holgate, S
    Fox, H
    Liu, J
    Castellsague, J
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (01) : S157 - S157
  • [24] PROPORTION OF PATIENTS WITH NASAL POLYPOSIS ACHIEVING CLINICALLY IMPORTANT IMPROVEMENTS IN QUALITY OF LIFE WITH OMALIZUMAB TREATMENT
    Lee, S. E.
    Yoo, B.
    Saenz, R.
    Braid, J.
    Millette, L.
    Rajput, Y.
    VALUE IN HEALTH, 2020, 23 : S349 - S349
  • [25] In search of clinically relevant parameters to monitor successful Omalizumab therapy in allergic asthma
    Probst, M.
    Gogolka, A.
    Kruell, M.
    Noga, O.
    ALLERGOLOGIE, 2011, 34 (06) : 299 - 306
  • [26] Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma (vol 36, pg 1001, 2021)
    Jung, Jae-Woo
    Park, Hae-Sim
    Park, Choon-Sik
    Cho, Sang-Heon
    Choi, Inseon S.
    Moon, Hee-Bom
    Kwon, Soon Seog
    Yoon, Ho Joo
    Park, Jung Won
    Lee, Jong-Myung
    Choi, Dong-Chull
    Choi, Byoung Whui
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2021, 36 (05): : 1260 - 1260
  • [27] Improvements in Reporting of Asthma Exacerbations in Efficacy and Safety Data with Tiotropium Add-on Therapy in Pediatric Patients.
    Szefler, S.
    Eickmeier, O.
    Vogelberg, C.
    Vrijlandt, E. J.
    Engel, M.
    El Azzi, G.
    Zaremba-Pechmann, L.
    Hamelmann, E.
    PEDIATRIC PULMONOLOGY, 2018, 53 : S103 - S104
  • [28] Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey
    Deschildre, Antoine
    Marguet, Christophe
    Salleron, Julia
    Pin, Isabelle
    Rittie, Jean-Luc
    Derelle, Jocelyne
    Abou Taam, Rola
    Fayon, Mickael
    Brouard, Jacques
    Dubus, Jean Christophe
    Siret, Daniel
    Weiss, Laurence
    Pouessel, Guillaume
    Beghin, Laurent
    Just, Jocelyne
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42 (05) : 1224 - 1233
  • [29] The impact of concomitant rhinitis on asthma-related quality of life and asthma control
    Vandenplas, O.
    Dramaix, M.
    Joos, G.
    Louis, R.
    Michils, A.
    Verleden, G.
    Vincken, W.
    Vints, A. -M.
    Herbots, E.
    Bachert, C.
    ALLERGY, 2010, 65 (10) : 1290 - 1297
  • [30] Asthma control in patients with asthma and allergic rhinitis receiving add-on montelukast therapy for 12 months: a retrospective observational study
    Borderias, Luis
    Mincewicz, Grzegorz
    Paggiaro, Pier Luigi
    Guilera, Magda
    Kocevar, Vasilisa Sazonov
    Taylor, Stephanie D.
    Badia, Xavier
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (04) : 721 - 730
12345